Background and Methods Cardiac troponin I (cTnI) is well recognized as a speci c marker for myocardial infarction. A fully automated, random access, uorescent immunoassay for cTnI was evaluated in comparison with an established assay (Stratus cTnI) using samples from healthy subjects and from patients with cardiac disease.
Results
The detection and precision were acceptable, and no interference was observed from bilirubin, triglycerides, haemoglobin, rheumatoid factor, drugs (aspirin, dopamine, digoxin) or heparin. Results on the Kryptor cTnI assay correlated with those on the Stratus II cTnI assay. The optimum Kryptor cTnI concentration for acute myocardial infarction was 0 ¢ 63 mg/L, with a sensitivity of 89% [95% con dence interval (CI): 75 ¢ 9--96 ¢ 3] and speci city of 98 ¢ 9% (95% CI: 93 ¢ 9--99 ¢ 8).
Conclusion Kryptor cTnI immunoassay is suitable for use in the diagnosis of myocardial infarction. Ann Clin Biochem 2002; 39: [145] [146] [147] Clinical interest in cardiac troponin I (cTnI) for the diagnosis of myocardial infarction 1 has led to the development of new assays. We evaluate here the analytical and clinical performance of the Kryptor cTnI assay (BRAHMS, Sartrouville, France) and compare it with the Stratus II cTnI assay (Dade Behring, La De¨fense, France).
The Kryptor is a random-access immunoanalyser that uses time-resolved ampli¢ed cryptate emission technology, based on a non-radiative transfer of energy. 2 The energy transfer takes place between two £uorescent tracers^a donor (europium cryptate) and an acceptor (XL665)^each bound to a monoclonal antibody. The cTnI present in the samples is sandwiched between two antibodies and the formation of the antigen^antibody complex results in signal ampli¢cation. The epitope mapping of the ¢rst antibody used is amino acids 41^49. The second antibody straddles two distinct parts of cTnI located within its central domain and C-terminal part. The calibrator is a mixture of human troponins (ternary complex I^CT ). The method uses 70 mL of sample and results are available after 14 min. If high concentrations of cTnI (4200 mg/L) are detected during the ¢rst few seconds of incubation, the sample is diluted and automatically re-analysed.
Interassay precision was determined with three di¡erent levels of a quality-control serum (BRAHMS, Sartrouville, France). Within-run and between-run precision were, respectively, 5¢5% and 9¢5% for 1¢5 mg/L, 1 ¢4% and 5 ¢0% for 40 mg/L and 1 ¢0% and 5¢1% for 100 mg/L (nˆ25 for each point). The lowest cTnI concentration that could be distinguished from zero (with a 95% upper con¢dence limit) was 0¢10 mg/L. The limit of quanti¢cation with acceptable precision [percentage coe¤cient of variance (%CV) 420] determined by the imprecision pro¢le was 0¢25 mg/L.
The e¡ect of heparin was examined by comparing plasma and serum samples collected from 23 patients. Mean relative recovery (de¢ned as the ratio of cTnI values in plasma compared with serum) was 0¢98+0¢18, and no statistical di¡erence was observed between cTnI values obtained using plasma or serum. It should be noted that the concentration of lithium heparinate used was 30 IU/mL, lower than that tested by Gerhardt et al. 3 Dopamine (53¢0 mg/L), digoxin (5350 mg/L), aspirin (51¢0 mg/L), bilirubin (5150 mmol/L), triglycerides (515¢0 mmol/ L), haemoglobin (520 g/L) and rheumatoid factor (30^700 kIU/L) had no e¡ect on the assay. The maximum di¡erence between expected and Short Report observed cTnI concentrations in spiked samples was 5¢1%.
Results from the Kryptor cTnI assay correlated with those from the Stratus II [Kryptorˆ1¢03 Stratus II70¢18; rˆ0 ¢96 (95% con¢dence interval (CI) of intercept: 70 ¢0094 to 0¢0406; 95% CI of slope: 1 ¢008 to 1 ¢092)]. The mean di¡erence between the two methods (Bland^Altman procedure) was 0¢08 mg/ L, and its standard deviation (SD) was 2 ¢ 3 mg/L. Eleven samples (4 ¢ 6%) were outside the mean+1 ¢ 96 SD range. These results indicate that the two tests could possess di¡erent reactivities towards the circulating forms of cTnI. 4 The reference values for Kryptor cTnI were determined by measuring cTnI in 137 apparently healthy people without cardiac disease [63 men (age range 18^90 years) and 74 women (age range 24^89 years)]. The distribution of cTnI was signi¢cantly di¡erent from normality (Kolmogorov^Smirnov test: P40 ¢ 01); 72% of cTnI values found in the normal population were less than the detection limit. No in£uence of age or gender was observed. The 97¢5th and 99th centile values were 0¢35 and 0¢37 mg/ L, respectively.
No signi¢cant di¡erence was observed between the results from the Stratus II and Kryptor analysers in samples from patients with stable angina (nˆ14), valvulopathy (nˆ18) and renal failure (creatinine 4150 mmol/L) (nˆ15). In 24 patients with unstable angina, 75% of Stratus cTnI and 67% Kryptor cTnI values were below the reference range. In four patients, Stratus cTnI values were above the cut-o¡ value for myocardial infarction (1¢0 mg/L). The proportion of cTnI-positive patients remained below that found with other cTnI assays. 4 cTnI values obtained in 89 patients without cardiac disease [58 men (age range 19^91 years) and 31 women (age range 40^90 years)] were compared with those obtained in 47 patients [35 men (age range 399 2 years) and 12 women (age range 62^91years)] who met the criteria of acute myocardial infarction according to the modi¢ed World Health Organization criteria. No signi¢cant di¡erence (Pˆ0¢348) was observed between the areas under the receiver-operator curves determined for the two cTnI assays (Kryptor cTnI: 0¢979; Stratus II: 0¢962). At a Kryptor cTnI concentration of 0¢63 mg/ L (%CVˆ5¢3), sensitivity reached 89% (95% CI: 75¢9^96¢3) and speci¢city 98 ¢ 9% (95% CI: 93 ¢ 9^99 ¢ 8) ( Fig. 1) . At 1 ¢ 0 mg/L, sensitivity of the Kryptor assay was 78% (95% CI: 63^89) and speci¢city 100%. For the same concentration, sensitivity and speci¢city for the Stratus II assay were 80% (95% CI: 65¢5^90¢4) and 97¢8% (95% CI: 92¢29 9¢7), respectively. Our results for patients with acute myocardial infarction are in agreement with those reported by Zaninotto et al. 5 In conclusion, we have demonstrated that the Kryptor cTnI assay had an analytical performance in accordance with recent recommendations. 1 Additional clinical evaluation will be necessary to determine speci¢c decision limits, in particular for risk strati¢cation. 
